Neurochemical Abnormalities in Patients with Type 1 Gaucher Disease on Standard of Care Therapy.
Type 1 Gaucher disease (GD1), a glycosphingolipid storage disorder caused by deficient activity of lysosomal glucocerebrosidase, is classically considered non-neuronopathic. However, current evidence challenges this view. Multiple studies show that mutations in GBA1 gene and decreased glucocerebrosidase activity are associated with increased risk for Parkinson disease. We tested the hypothesis that subjects with GD1 will show neurochemical abnormalities consistent with cerebral involvement. We performed Magnetic Resonance Spectroscopy at 7 tesla to quantify neurochemical profiles in participants with GD1 (n=12) who are on stable therapy. Age and gender matched healthy participants served as controls (n=13). Neurochemical profiles were obtained from parietal white matter (PWM), posterior cingulate cortex (PCC) and putamen. Further, in the GD1 group, the neurochemical profiles were compared between individuals with and without a single L444P allele. We observed significantly lower levels of key neuronal markers, N-acetylaspartate, γ-aminobutyric acid, glutamate and glutamate-to-glutamine ratio in PCC of participants with GD1 compared to healthy controls (p<0.015). Glutamate concentration was also lower in the putamen in GD1 (p=0.01). Glucose + taurine concentration was significantly higher in PWM (p=0.04). Interestingly, individuals without L444P had significantly lower aspartate and N-acetylaspartylglutamate in PCC (both p<0.001), although this group was 7 years younger than those with an L444P allele. This study demonstrates neurochemical abnormalities in individuals with GD1, for which clinical and prognostic significance remains to be determined. Further studies in a larger cohort are required to confirm an association of neurochemical levels with mutation status and glucocerebrosidase structure and function. This article is protected by copyright. All rights reserved.